Literature DB >> 30172916

Comparison of evaluation techniques, including digital image analysis, for MYC protein expression by immunohistochemical stain in aggressive B-cell lymphomas.

Meghan Hupp1, Sarah Williams1, Brian Dunnette1, Katelyn M Tessier2, Elizabeth L Courville3.   

Abstract

Incorporation of an MYC immunohistochemical stain in the workup of large B-cell lymphomas has become common in hematopathology practice. Evaluation of this stain can be difficult because of staining heterogeneity and can have interobserver variability, particularly when performed on the entire tumor sections. We identified 87 cases of aggressive B-cell lymphoma (34 core needle and 53 excisional biopsies) and compared the following methods of MYC immunohistochemical staining evaluation: the original pathologist's interpretation, a systematic retrospective method of evaluation by manual analysis, and a retrospective method of evaluation by digital image analysis (using scanned slides analyzed via the Aperio Nuclear algorithm). Overall, concordance among these methods was around 80% with κ statistics showing good agreement. However, nearly one-third of our cases had a percent MYC positivity in the 30% to 50% range, and for these cases, concordance among the various methods was marginal/poor. This suggests limited utility as a prognostic or predictive marker using 40% as a cutoff value. In our series, core biopsy specimens were poor predictors of MYC gene rearrangement, and there was no association between MYC immunohistochemical stain and MYC gene gain/amplification. Our retrospective digital image analysis showed strong correlation in MYC percent positivity with our retrospective manual review (correlation coefficient of 0.90) and similar concordance to pathologist interpretation as among pathologists, suggesting that digital image analysis is a viable alternative to manual determination of MYC percent positivity. Digital image analysis provides further opportunities for more sophisticated and standardized scoring systems, which may be helpful in future prognostic/predictive studies.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DLBCL; Diffuse large B-cell lymphoma; Digital image analysis; High-grade B-cell lymphoma; Immunohistochemistry; MYC; Prognosis

Mesh:

Substances:

Year:  2018        PMID: 30172916      PMCID: PMC6365198          DOI: 10.1016/j.humpath.2018.08.019

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  20 in total

1.  Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologists.

Authors:  Amer Z Mahmoud; Tracy I George; David R Czuchlewski; Qian-Yun Zhang; Carla S Wilson; Cordelia E Sever; Alexei G Bakhirev; Dahua Zhang; Nichole L Steidler; Kaaren K Reichard; Huining Kang; Kathryn Foucar; Mohammad A Vasef
Journal:  Mod Pathol       Date:  2014-11-28       Impact factor: 7.842

Review 2.  Digital imaging in pathology: whole-slide imaging and beyond.

Authors:  Farzad Ghaznavi; Andrew Evans; Anant Madabhushi; Michael Feldman
Journal:  Annu Rev Pathol       Date:  2012-11-15       Impact factor: 23.472

3.  Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center.

Authors:  Patrick L Fitzgibbons; Linda A Bradley; Lisa A Fatheree; Randa Alsabeh; Regan S Fulton; Jeffrey D Goldsmith; Thomas S Haas; Rouzan G Karabakhtsian; Patti A Loykasek; Monna J Marolt; Steven S Shen; Anthony T Smith; Paul E Swanson
Journal:  Arch Pathol Lab Med       Date:  2014-03-19       Impact factor: 5.534

4.  BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.

Authors:  Naoko Tsuyama; Seiji Sakata; Satoko Baba; Yuko Mishima; Noriko Nishimura; Kyoko Ueda; Masahiro Yokoyama; Yasuhito Terui; Kiyohiko Hatake; Masanobu Kitagawa; Naoki Ishizuka; Naoto Tomita; Kengo Takeuchi
Journal:  Blood       Date:  2017-05-18       Impact factor: 22.113

5.  Her2 immunohistochemical evaluation by traditional microscopy and by digital analysis, and the consequences for FISH testing.

Authors:  Thomas Marcuzzo; Fabiola Giudici; Elisa Ober; Clara Rizzardi; Cristina Bottin; Fabrizio Zanconati
Journal:  Pathol Res Pract       Date:  2016-08-02       Impact factor: 3.250

6.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Alexandra Valera; Armando López-Guillermo; Teresa Cardesa-Salzmann; Fina Climent; Eva González-Barca; Santiago Mercadal; Iñigo Espinosa; Silvana Novelli; Javier Briones; José L Mate; Olga Salamero; Juan M Sancho; Leonor Arenillas; Sergi Serrano; Nadina Erill; Daniel Martínez; Paola Castillo; Jordina Rovira; Antonio Martínez; Elias Campo; Luis Colomo
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

7.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.

Authors:  Shimin Hu; Zijun Y Xu-Monette; Alexander Tzankov; Tina Green; Lin Wu; Aarthi Balasubramanyam; Wei-min Liu; Carlo Visco; Yong Li; Roberto N Miranda; Santiago Montes-Moreno; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; Xiaoying Zhao; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Fan Zhou; Graham W Slack; Randy D Gascoyne; Meifeng Tu; Daina Variakojis; Weina Chen; Ronald S Go; Miguel A Piris; Michael B Møller; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-02-28       Impact factor: 22.113

8.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.

Authors:  Heike Horn; Marita Ziepert; Claudia Becher; Thomas F E Barth; Heinz-Wolfram Bernd; Alfred C Feller; Wolfram Klapper; Michael Hummel; Harald Stein; Martin-Leo Hansmann; Christopher Schmelter; Peter Möller; Sergio Cogliatti; Michael Pfreundschuh; Norbert Schmitz; Lorenz Trümper; Reiner Siebert; Markus Loeffler; Andreas Rosenwald; German Ott
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

9.  MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice.

Authors:  Michael J Kluk; Caleb Ho; Hongbo Yu; Benjamin J Chen; Donna S Neuberg; Paola Dal Cin; Bruce A Woda; Geraldine S Pinkus; Scott J Rodig
Journal:  Am J Clin Pathol       Date:  2016-02-01       Impact factor: 2.493

10.  Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas.

Authors:  Michael J Kluk; Bjoern Chapuy; Papiya Sinha; Alyssa Roy; Paola Dal Cin; Donna S Neuberg; Stefano Monti; Geraldine S Pinkus; Margaret A Shipp; Scott J Rodig
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

View more
  1 in total

1.  Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.

Authors:  Daniel J Landsburg; Mitchell E Hughes; Alexa Koike; David Bond; Kami J Maddocks; Ling Guo; Allison M Winter; Brian T Hill; Sarah L Ondrejka; Eric D Hsi; Sunita D Nasta; Jakub Svoboda; Stephen J Schuster; Agata M Bogusz
Journal:  Blood Adv       Date:  2019-01-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.